Net margin is calculated as Net Income divided by its Revenue. Philogen SpA's Net Income for the
six
months ended in Dec. 2025 was €244.6 Mil. Philogen SpA's Revenue for the
six
months ended in Dec. 2025 was €308.8 Mil. Therefore, Philogen SpA's net margin for the quarter that ended in Dec. 2025 was 79.19%.
The historical rank and industry rank for Philogen SpA's Net Margin % or its related term are showing as below:
MIL:PHIL'
s Net Margin % Range Over the Past 10 Years
Min: -630.01 Med: -24.66 Max: 73.07
Current: 73.07
MIL:PHIL's Net Margin % is ranked better than 97.04% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs MIL:PHIL: 73.07
Philogen SpA (MIL:PHIL) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Philogen SpA Net Margin % Related Terms
Philogen SpA Net Margin % Historical Data
* Premium members only.
The historical data trend for Philogen SpA's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHIL vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Philogen SpA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's Net Margin % distribution charts can be found below:
* The bar in red indicates where Philogen SpA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Philogen SpA (MIL:PHIL) has a Net Margin % of 79.19% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Philogen SpA and its competitors. According to the industry distribution chart, Philogen SpA ranks #28 out of 946 companies in the Biotechnology industry, placing it in the top 3%.
Is Philogen SpA's Net Margin % too high?
Philogen SpA's current Net Margin % is 79.19%. Based on the distribution chart, Philogen SpA ranks #28 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Philogen SpA has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #28 out of 946 companies for Net Margin %. This places Philogen SpA in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Philogen SpA and its competitors. Philogen SpA's current Net Margin % is 79.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €227.22, compared to a current price of €23.30 — trading 89.7% below its estimated fair value. The current Net Margin % is 79.19%. Philogen SpA's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Net Margin % is 79.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €23.30 is trading 89.7% below its estimated GF Value™ of €227.22.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
Net Margin %: 79.19%
GF Value™: €227.22 vs. price of €23.30 (89.7% below fair value)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
62GF Score
Get the complete analysis for MIL:PHIL
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
